Signet Therapeutics, a pioneering biotech company, has achieved a significant milestone with the US Food and Drug Administration (FDA)’s Investigational New Drug (IND) approval of its drug candidate, sigx1094, for the treatment of diffuse gastric cancer (DGC). This marks the introduction of the first targeted therapy for DGC, a disease currently lacking effective treatment options. […]
Lantern Pharma Inc. (NASDAQ: LTRN) announced a strategic collaboration with French biotech company Oregon Therapeutics to enhance the development of XCE853, a first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate. The partnership, utilizing Lantern Pharma’s proprietary RADR AI platform, aims to identify biomarkers and gene signatures that will guide XCE853’s clinical application in treating various […]
